[April 16, 2018] |
|
Navidea Biopharmaceuticals to Present at 2nd Annual NASH Summit
Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the
Company"), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today announced it will
present at the 2nd Annual NASH Summit in Boston, MA being
held April 23-25, 2018. Michael Goldberg, President and Chief Executive
Officer, will be giving a new presentation focused on Navidea's NASH
research; the presentation will be available on Navidea's website
following the conference.
Event: 2nd Annual NASH Conference Presentation
Date: Wednesday, April 25th Presentation Time: 11:30am
EST Location: Revere Hotel Boston Common, Boston, MA
To schedule a meeting with Navidea management at the conference, please
contact Navidea Investor Relations at [email protected].
About Navidea Navidea Biopharmaceuticals, Inc. NYSE
American: NAVB) is a biopharmaceutical company focused on the
development of precision immunodiagnostic agents and immunotherapeutics.
Navidea is developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites and
pathways of disease and enable better diagnostic accuracy, clinical
decision-making, and targeted treatment. Navidea's Manocept platform is
predicated on the ability to specifically target the CD206 mannose
receptor expressed on activated macrophages. The Manocept platform
serves as the molecular backbone of Tc 99m tilmanocept, the first
product developed and commercialized by Navidea based on the platform.
The development activities of the Manocept immunotherapeutic platform
are being conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics, Inc. Navidea's strategy is to deliver superior
growth and shareholder return by bringing to market novel products and
advancing the Company's pipeline through global partnering and
commercialization efforts.
For more information, please visit www.navidea.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180416005587/en/
[ Back To TMCnet.com's Homepage ]
|